Navigation Links
NaZura BioHealth Spun-out from Elcelyx Therapeutics to Advance Lovidia for Weight Management

SAN DIEGO, Sept. 4, 2013 /PRNewswire/ -- Elcelyx Therapeutics announced today that it has formed NaZura BioHealth, a separate company established to focus on the development of Gut Sensory Modulators (GSM) including lead product Lovidia™, a dietary supplement for weight management. Elcelyx retains pharmaceutical product candidate NewMet™, the company's proprietary delayed-release formulation of metformin for the treatment of patients with Type 2 diabetes. Elcelyx has funded NaZura with a credit line of $5 million, which will be used for clinical development of Lovidia and pre-commercial activities.


"We are separating the Lovidia and NewMet assets in order to maximize their value as we approach critical development milestones," said Alain D. Baron, M.D., president and chief executive officer of both NaZura BioHealth and Elcelyx Therapeutics. "NaZura BioHealth will commercialize Lovidia, a one-of-a-kind weight loss product with launch planned for early second quarter 2014, and Elcelyx Therapeutics will continue to advance NewMet for Type 2 diabetes."

Lovidia, a dietary supplement, is being developed with the level of rigor typical of pharmaceutical products. An early Lovidia prototype demonstrated statistically significant and progressive weight loss through 16 weeks in a randomized, placebo-controlled, double-blind clinical study. In 121 evaluable overweight or obese subjects, three times as many people lost 5% of their body weight compared to placebo. This was accomplished without diet or exercise modification and the tolerability and safety profile of the prototype was similar to placebo. In other short-term studies, preliminary formulations of Lovidia increased the body's food-driven production of natural satiety and gluco-regulatory gut hormones twofold; with the same number of calories, subjects had twice the satiety signal.

An optimized version of Lovidia is now being readied for market. It is expected that this optimized product will produce greater weight loss than that seen with the prototype. A 16-week clinical study using the optimized Lovidia product is now underway. This placebo-controlled, double-blind weight loss study in 240 overweight and obese subjects is fully enrolled with results expected in the fourth quarter of 2013.

Lovidia is a proprietary mix of dietary ingredients designated by the U.S. Food and Drug Administration as Generally Recognized as Safe (GRAS) and FDA-approved food additives.

NaZura BioHealth and Elcelyx Therapeutics share the same board of directors, including Ralph Christoffersen, Ph.D., Morgenthaler Ventures (chairman); Alain D. Baron, M.D.; Rick Barry, GSM Fund LLC; Brook Byers, Kleiner Perkins Caufield & Byers; Jim Glasheen, Ph.D., Technology Partners; Ginger L. Graham, former President and CEO, Amylin Pharmaceuticals.

About NaZura BioHealth, Inc.
NaZura BioHealth is developing consumer healthcare products based on its proprietary Gut Sensory Modulation (GSM) technology. GSMs are delivered to the lower gut where they intensify the body's natural food-driven signals that trigger a sense of fullness and facilitate glucose regulation. NaZura plans to commercialize its lead product, Lovidia™, a dietary supplement for weight management, in early second quarter 2014. For more information, visit

About Elcelyx Therapeutics, Inc.
Elcelyx Therapeutics is developing pharmaceutical product candidate NewMet™ for use by Type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. NewMet presents a near-term, blockbuster commercial opportunity.  Elcelyx is based in San Diego, CA. For more information, visit

SOURCE NaZura BioHealth, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elcelyx Therapeutics NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study
2. Elcelyx Therapeutics Reports Positive Data for NewMet in Type 2 Diabetes at 2013 American Diabetes Association Scientific Sessions
3. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
4. Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia
5. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
6. Aratana Therapeutics Drives Awareness of Pet Therapeutic Opportunity During "CVC Week" in Kansas City
7. Mast Therapeutics To Present At The Rodman & Renshaw 15th Annual Healthcare Conference On September 10
8. PTC Therapeutics to Present at Upcoming Investor Conferences
9. Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event
10. Carolus Therapeutics and The Alpha-1 Project Collaborate to Validate CT-2009 Target as Important in Human Disease
11. Echo Therapeutics Announces Management Changes
Post Your Comments:
(Date:11/24/2015)... 24, 2015  Boston Scientific Corporation (NYSE: BSX ... Annual Healthcare Conference on December 8, in ... , vice president, Investor Relations, will participate in a ... approximately 8:35 a.m. ET. --> Susie Lisa ... 30-minute question-and-answer session with the host analyst beginning at ...
(Date:11/24/2015)... Nov. 24, 2015  Enova Illumination is pleased to ... Helsinki, Finland to combine their world ... the cutting edge of medical visualization: Enova is the ... the United States and Novocam is the ... provide the world,s most powerful battery-operated LED headlight with ...
(Date:11/24/2015)... -based Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ... production and dispensing of novel compounded pharmaceuticals.  The ... including ophthalmology, urology, sinus and integrative medicine.  Imprimis ... four facilities located in California ... New Jersey and Pennsylvania.  For more ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... Chiropractic ... University-Kansas City (CU-KC), in Overland Park, Kansas. Benson, a fifth-trimester student in ... Carl S. Cleveland III on October 16. , “Katie is very excited and ...
(Date:11/24/2015)... ... November 24, 2015 , ... Sir Grout of Baltimore ... TrustDale certification. The award recognizes good companies for excellence in service and a ... grout, and hard surface restoration company earned this recognition after a thorough review ...
(Date:11/24/2015)... ... 2015 , ... Bibliomotion is thrilled to announce the launch of ... Diversity by Nancy M. Schlichting, Chief Executive Officer of Henry Ford Health ... the needs of patients and their families, shaped my desire to improve the system ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Kevin Day, local family ... community stress less this holiday season. During the Indiana winter months, Vitamin D ... and the team at AlignLife want to help provide the tools needed to combat ...
(Date:11/24/2015)... ... November 24, 2015 , ... All her life, Don Peck’s mother wondered if she was a ... might have been. After a 25-year search for information, Don and his aunt discovered ... a last name. Turns out, it was Don’s father who was descended from not ...
Breaking Medicine News(10 mins):